Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|June 15, 2022
Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 VariantsAshley C Beavis, Zhuo Li, Kelsey Briggs, et al.
Ebiomedicine|August 6, 2022
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccineDavid W Hawman, Kimberly Meade-White, Chad Clancy, et al.
JCI Insight|November 12, 2021
Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populationsLouisa Helms, Silvia Marchiano, Ian B Stanaway, et al.
Medrxiv : the Preprint Server for Health Sciences|August 29, 2022
Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against OmicronLinhui Hao, Tien-Ying Hsiang, Ronit R Dalmat, et al.
JCI Insight|April 19, 2022
T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severityRebecca Elyanow, Thomas M Snyder, Sudeb C Dalai, et al.
Viruses|February 28, 2023
Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against OmicronLinhui Hao, Tien-Ying Hsiang, Ronit R Dalmat, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 13, 2023
Duration of viral infectiousness and correlation with symptoms and diagnostic testing in non-hospitalized adults during acute SARS-CoV-2 infection: A longitudinal cohort studyPaul K Drain, Ronit R Dalmat, Linhui Hao, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2Thomas W Linsky, Renan Vergara, Nuria Codina, et al.
Elife|August 3, 2021
Endomembrane targeting of human OAS1 p46 augments antiviral activityFrank W Soveg, Johannes Schwerk, Nandan S Gokhale, et al.
Journal of Medicinal Chemistry|August 19, 2023
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green MonkeysRichard L Mackman, Rao V Kalla, Darius Babusis, et al.
Pageof 4